DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
61	自己免疫性溶血性貧血	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04253236 (ClinicalTrials.gov)	August 11, 2020	21/1/2020	To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).	A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia	Warm Autoimmune Hemolytic Anemia	Drug: RVT-1401 680 mg/weekly;Drug: RVT-1401 340 mg/weekly	Immunovant Sciences GmbH	NULL	Recruiting	18 Years	N/A	All	16	Phase 2	United States;Israel;Korea, Republic of;Spain;Thailand;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

August 11, 2020

21/1/2020

To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

Drug: RVT-1401 680 mg/weekly;Drug: RVT-1401 340 mg/weekly

Immunovant Sciences GmbH

NULL

Recruiting

18 Years

N/A

All

Phase 2

United States;Israel;Korea, Republic of;Spain;Thailand;United Kingdom